webinars

PAST WEBINARS

High Translatable DIO Rodent Model: Accelerating Weight Loss Drug Discovery

Obesity remains a critical global health threat, affecting over one billion people worldwide and exacerbating risks for type 2 diabetes, cardiovascular diseases, and fatty liver disease. The pharmaceutical landscape is witnessing rapid transformation through novel oral GLP-1 agents, long-acting injectables, and multi-target therapies that are redefining treatment possibilities.
Watch Now
PAST WEBINARS

ADME and Bioanalytical Strategies for ADCs: Challenges, Emerging Technologies, and Regulatory Considerations

Antibody-drug conjugates (ADCs) are transforming cancer treatment, but their development brings unique challenges in the DMPK field, including ADME, bioanalysis, and regulatory registration. This webinar explores integrated DMPK and bioanalytical strategies for ADC discovery and development, grounded in recent analytical advances, global guidelines, and real-world experience.
Watch Now
PAST WEBINARS

Clinical Trial Application Success: CMC and Regulatory Insights from the US to Europe

The Investigational New Drug (IND) application in the US and Clinical Trial Application (CTA) in Europe are key milestones in advancing innovative therapies to clinical development. This webinar will discuss the technical and regulatory aspects of IND and CTA submissions in the US and Europe.
Watch Now
PAST WEBINAR

Optimizing Protocols to Seamlessly Transfer Med. Chem. Synthesis to Process Development

The transition from drug discovery to process development presents significant challenges. Developing scalable synthetic routes, sourcing high-quality reagents in large quantities, ensuring efficient technology transfer, and aligning tight project timelines across departments to meet customer needs can all create obstacles. These hurdles can delay the delivery of toxicology and clinical batches of the API, leading to costl
PAST WEBINARS

Fueling TPD Drug Discovery: In Vitro Evaluation and Synthesis Strategies

Target Protein Degradation (TPD) has merged as an innovative "event-driven" therapeutic approach, overcoming the limitations of traditional small molecule drugs by enabling the targeting of "undruggable" proteins with high potency and selectivity. It offers a significant advantage by targeting these proteins at low doses, thus bringing new hope for clinical treatment. Molecular glues and PROTACs have emerged as rapidly evolving molecules in the TPD field, however, their complex mechanisms introduce significant hurdles in pre-clinical drug discovery.
Watch Now
PAST WEBINARS

Exploring Peptide In-Vitro ADME Properties: From Natural Peptides to Synthetic Analogues

Join us Friday, June 13, 2025 | 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central) with interest in peptide drug development, formulation scientists, pharmacokinetic experts and anyone interested in advancing the stability and performance of peptide-based therapeutics.
Watch Now
Total 16 123
✉️Contact Us
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all